Inhibikase Therapeutics, Inc. Cash and Cash Equivalents
Inhibikase Therapeutics, Inc. (IKT) had Cash and Cash Equivalents of $178.80 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-03-26
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $178.80M.
- 2024-12-31: Cash and Cash Equivalents, at Carrying Value $97.50M; Cash and Cash Equivalents, at Carrying Value as first filed $56.50M.
- 2023-12-31: Cash and Cash Equivalents, at Carrying Value $9.20M; Cash and Cash Equivalents, at Carrying Value as first filed $9.17M.
- 2022-12-31: Cash and Cash Equivalents, at Carrying Value $7.19M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2025-12-31 | $178.80M 10-K · filed 2026-03-26 | |
| 2024-12-31 | $97.50M 10-K · filed 2026-03-26 | $56.50M 10-K · filed 2025-03-27 |
| 2023-12-31 | $9.20M 10-K · filed 2025-03-27 | $9.17M 10-K · filed 2024-03-27 |
| 2022-12-31 | $7.19M 10-K · filed 2024-03-27 | |
| 2021-12-31 | $40.75M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |